IL158285A0 - Peptide-based immunization therapy for treatment of atherosclerosis and development of peptide-base assay for determination of immune responses against oxidized low density lipoprotein - Google Patents

Peptide-based immunization therapy for treatment of atherosclerosis and development of peptide-base assay for determination of immune responses against oxidized low density lipoprotein

Info

Publication number
IL158285A0
IL158285A0 IL15828502A IL15828502A IL158285A0 IL 158285 A0 IL158285 A0 IL 158285A0 IL 15828502 A IL15828502 A IL 15828502A IL 15828502 A IL15828502 A IL 15828502A IL 158285 A0 IL158285 A0 IL 158285A0
Authority
IL
Israel
Prior art keywords
peptide
atherosclerosis
determination
development
treatment
Prior art date
Application number
IL15828502A
Other languages
English (en)
Original Assignee
Forskarpatent I Syd Ab Cedars
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE0101232A external-priority patent/SE0101232D0/xx
Application filed by Forskarpatent I Syd Ab Cedars filed Critical Forskarpatent I Syd Ab Cedars
Publication of IL158285A0 publication Critical patent/IL158285A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
IL15828502A 2001-04-05 2002-04-05 Peptide-based immunization therapy for treatment of atherosclerosis and development of peptide-base assay for determination of immune responses against oxidized low density lipoprotein IL158285A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE0101232A SE0101232D0 (sv) 2001-04-05 2001-04-05 Peptide-based immunization therapy for treatment of atherosclerosis and development of peptide-based elisa for determination of immune responses against oxidized low density liprotein
SE0103754A SE0103754L (sv) 2001-04-05 2001-11-09 Peptider från apolipoprotein B, användning därav immunisering, diagnosmetod eller terapeutisk behandling av ischemiska kardiovaskulära sjukdomar, samt farmaceutisk komposition och vaccin innehållande sådan peptid
PCT/SE2002/000679 WO2002080954A1 (en) 2001-04-05 2002-04-05 Peptide-based immunization therapy for treatment of atherosclerosis and development of peptide-based assay for determination of immune responses against oxidized low density lipoprotein

Publications (1)

Publication Number Publication Date
IL158285A0 true IL158285A0 (en) 2004-05-12

Family

ID=26655437

Family Applications (4)

Application Number Title Priority Date Filing Date
IL15828502A IL158285A0 (en) 2001-04-05 2002-04-05 Peptide-based immunization therapy for treatment of atherosclerosis and development of peptide-base assay for determination of immune responses against oxidized low density lipoprotein
IL158285A IL158285A (en) 2001-04-05 2003-10-07 Peptides for preparing medicament for immuno- therapy of atherosclerosis and development of peptide-base assay for determination of immune responses against oxidized low density lipoprotein
IL188286A IL188286A0 (en) 2001-04-05 2007-12-20 Peptide-based immunization therapy for treatment of atherosclerosis and development of peptide-based assay for determination of immune responses against oxidized low density lipoprotein
IL195356A IL195356A0 (en) 2001-04-05 2008-11-18 Peptide-based immunization therapy for treatment of atherosclerosis and development of peptide-based assay for determination of immune responses against oxidized low density lipoprotein

Family Applications After (3)

Application Number Title Priority Date Filing Date
IL158285A IL158285A (en) 2001-04-05 2003-10-07 Peptides for preparing medicament for immuno- therapy of atherosclerosis and development of peptide-base assay for determination of immune responses against oxidized low density lipoprotein
IL188286A IL188286A0 (en) 2001-04-05 2007-12-20 Peptide-based immunization therapy for treatment of atherosclerosis and development of peptide-based assay for determination of immune responses against oxidized low density lipoprotein
IL195356A IL195356A0 (en) 2001-04-05 2008-11-18 Peptide-based immunization therapy for treatment of atherosclerosis and development of peptide-based assay for determination of immune responses against oxidized low density lipoprotein

Country Status (18)

Country Link
EP (42) EP2295463A1 (xx)
JP (6) JP2004529143A (xx)
CN (4) CN103122031B (xx)
AT (2) ATE415423T1 (xx)
AU (1) AU2002246484B8 (xx)
BR (1) BR0208685A (xx)
CA (3) CA2606839C (xx)
CY (1) CY1108817T1 (xx)
DE (1) DE60230029D1 (xx)
DK (3) DK1383526T3 (xx)
EE (2) EE200700052A (xx)
ES (2) ES2317999T3 (xx)
IL (4) IL158285A0 (xx)
PL (4) PL367301A1 (xx)
PT (1) PT1383526E (xx)
RU (1) RU2296582C2 (xx)
SE (1) SE0103754L (xx)
WO (1) WO2002080954A1 (xx)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0103754L (sv) * 2001-04-05 2002-10-06 Forskarpatent I Syd Ab Peptider från apolipoprotein B, användning därav immunisering, diagnosmetod eller terapeutisk behandling av ischemiska kardiovaskulära sjukdomar, samt farmaceutisk komposition och vaccin innehållande sådan peptid
US20030105003A1 (en) 2001-04-05 2003-06-05 Jan Nilsson Peptide-based immunization therapy for treatment of atherosclerosis and development of peptide-based assay for determination of immune responses against oxidized low density lipoprotein
IL161110A0 (en) 2001-09-28 2004-08-31 Esperion Therapeutics Inc Prevention and treatment of restenosis by local admistration of drug
CA2500895A1 (en) * 2002-10-04 2004-04-15 Forskarpatent I Syd Ab Peptide-based passive immunization therapy for treatment of atherosclerosis
SE0302312D0 (sv) 2002-10-04 2003-08-27 Forskarpatent I Syd Ab Peptide-based passive immunization therapy for treatment of atherosclerosis
SE0302422D0 (sv) * 2003-09-11 2003-09-11 Forskarpatent I Syd Ab Peptide-based immunization therapy for treatment of atherosclerosis
SE0400683D0 (sv) * 2004-03-19 2004-03-19 Forskarpatent I Syd Ab Use of modified extracellular matrix proteins in diagnosis and treatment of a atherosclerosis
JP2007531537A (ja) 2004-04-06 2007-11-08 セダーズ−シナイ　メディカル　センター アポリポタンパク質ａ−ｉおよびアポリポタンパク質ａ−ｉｍｉｌａｎｏをコードする組換えアデノ随伴ウイルスベクターによる血管疾患の予防および処置
US8012483B2 (en) * 2004-04-15 2011-09-06 Athera Biotechnologies Ab Phosphorylcholine conjugates and corresponding antibodies
EP1676602A1 (en) * 2005-01-04 2006-07-05 Institut National De La Sante Et De La Recherche Medicale (Inserm) Continuous administration of epitopes derived from protein present in atherosclerotic plaque for the treatment of atherosclerosis
GB0517878D0 (en) 2005-09-02 2005-10-12 Bioinvent Int Ab Immunotherapeutic treatment
EP2115466A4 (en) * 2006-12-22 2010-07-28 Abbott Lab HEART CIRCUIT AUTOIMMUNE DISEASE TEST GROUP AND METHOD FOR USE THEREOF
WO2008104194A1 (en) * 2007-02-28 2008-09-04 Bioinvent International Ab Oxidized ldl and antibodies thereto for the treatment of atheroscleroti c plaques
MY156814A (en) 2007-03-15 2016-03-31 Novartis Ag Organic compounds and their uses
EP2208073B1 (en) * 2007-11-05 2020-01-15 Nordic Bioscience A/S Biochemical markers for cvd risk assessment
US20100041663A1 (en) 2008-07-18 2010-02-18 Novartis Ag Organic Compounds as Smo Inhibitors
US20110287955A1 (en) * 2008-08-15 2011-11-24 National University Corporation Chiba University Polypeptide marker for diagnosis of arteriosclerosis, method for detection of arteriosclerosis by using the maker or the like, and kit for diagnosis of arteriosclerosis
WO2011060329A1 (en) 2009-11-14 2011-05-19 Kuang-Yuh Chyu Immunomodulatory methods and systems for treatment and/or prevention of atherosclerosis
US8506964B2 (en) 2010-02-05 2013-08-13 Cardiovax, Llc Fusion proteins and related compositions, methods and systems for treatment and/or prevention of atherosclerosis
US20130142760A1 (en) 2010-08-18 2013-06-06 Cedars-Sinai Medical Center Atherosclerosis inhibition via modulation of monocyte-macrophage phenotype using apo a-i milano gene transfer
US9205139B2 (en) 2010-11-12 2015-12-08 Cardiovax, Llc Immunomodulatory methods and systems for treatment and/or prevention of aneurysms
RU2013126626A (ru) 2010-11-12 2014-12-20 Седарс-Синаи Медикал Сентер Иммуномодулирующие способы и системы для лечения и/или предотвращения гипертензий
WO2012065135A2 (en) 2010-11-12 2012-05-18 Cedars-Sinai Medical Center Immunomodulatory compositions, methods and systems comprising immunogenic fragments of apob100
EP2742068B1 (en) 2011-08-09 2019-04-03 Athera Biotechnologies AB New antibodies against phosphorylcholine
US9796786B2 (en) 2011-08-09 2017-10-24 Athera Biotechnologies Ab Antibodies binding to phosphorylcholine (PC) and/or PC conjugates
RU2495048C1 (ru) * 2012-04-18 2013-10-10 Андрей Валентинович Исаев Пептид, обладающий антиатеросклеротическим действием и композиция для профилактики и лечения атеросклероза сосудов
CN104768970B (zh) 2012-11-06 2019-11-15 日内瓦大学 模拟肽
CN103520713B (zh) * 2013-10-16 2015-10-28 西北农林科技大学 一种ApoB100酵母重组疫苗及其制备方法和应用
CN103860470A (zh) * 2014-03-05 2014-06-18 贵州中泰生物科技有限公司 一种口服高密度脂蛋白脂质体的制备方法
CN105315364B (zh) * 2014-06-17 2018-09-18 广州文瑞生物科技有限公司 胶原蛋白vi疫苗预防动脉粥样硬化
CN114085283A (zh) * 2015-05-19 2022-02-25 拉·约拉过敏反应及免疫医学研究所 调节炎症应答及治疗不良心血管事件、病和粥样硬化的人apob100表位、方法和用途
US10858422B2 (en) 2016-05-31 2020-12-08 Abcentra, Llc Methods for treating systemic lupus erythematosus with an anti-apolipoprotein B antibody
CN108478817B (zh) * 2018-03-16 2020-10-27 北京大学 一种动脉粥样硬化检测试剂及其制备方法
WO2019232081A1 (en) 2018-05-29 2019-12-05 Abcentra, Llc Compositions and methods for treatment of rheumatoid arthritis and accelerated atherosclerosis
CN112689512A (zh) 2018-05-29 2021-04-20 艾比中心有限责任公司 用于治疗银屑病的组合物和方法

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4970144A (en) * 1984-12-31 1990-11-13 International Genetic Engineering Peptide fragments of human apolipoprotein, type-specific antibodies and methods of use
US5972890A (en) 1988-05-02 1999-10-26 New England Deaconess Hospital Corporation Synthetic peptides for arterial imaging
WO1993018067A1 (en) * 1992-03-06 1993-09-16 Abbott Laboratories Immunocapture assay for direct quantitation of specific lipoprotein cholesterol levels
WO1994000592A1 (en) * 1992-06-26 1994-01-06 Exocell, Inc. Monoclonal antibodies against glycated low density lipoprotein
EP0671926B1 (en) * 1992-08-11 2002-11-13 President And Fellows Of Harvard College Immunomodulatory peptides
KR0185334B1 (ko) 1995-11-02 1999-04-01 김은영 인간 혈장 아포지단백질 비-100에 결합하는 생쥐 항체를 암호하는 씨디엔에이
GB9609702D0 (en) * 1996-05-09 1996-07-10 Royal Free Hosp School Med Anticoagulant peptides
GB9620153D0 (en) * 1996-09-27 1996-11-13 Univ Strathclyde Non-naturally occurring lipoprotein particle
GB9705831D0 (en) * 1997-03-20 1997-05-07 Univ Leicester Oxidised ldl
US6635623B1 (en) * 1997-06-13 2003-10-21 Baylor College Of Medicine Lipoproteins as nucleic acid vectors
US6225070B1 (en) 1997-08-07 2001-05-01 The Regents Of The University Of California Antibodies to oxidation-specific epitopes on lipoprotein and methods for their use in detecting, monitoring and inhibiting the growth of atheroma
US6156315A (en) * 1997-10-10 2000-12-05 The Trustees Of Columbia University In The City Of New York Method for inhibiting the binding of low density lipoprotein to blood vessel matrix
US6309844B1 (en) * 1997-10-15 2001-10-30 Fujirebio Inc. Anti-apo-B-48 monoclonal antibody, hybridoma producing the same, and method for measuring apo-B-48 using the same
US6579682B1 (en) * 1998-03-10 2003-06-17 The Regents Of University Of California Methods and tools for identifying compounds which modulate atherosclerosis by impacting LDL-proteoglycan binding
WO2000002920A1 (en) * 1998-07-13 2000-01-20 University Of Otago Inhibition of lipoprotein formation
IL126447A (en) * 1998-10-04 2004-09-27 Vascular Biogenics Ltd An immune preparation that confers tolerance in oral administration and its use in the prevention and / or treatment of atherosclerosis
CA2389849A1 (en) * 1999-10-26 2001-05-10 Regents Of The University Of California Reagents and methods for diagnosing, imaging and treating atherosclerotic disease
AU2001233114A1 (en) * 2000-02-04 2001-08-14 Aeomica, Inc. Methods and apparatus for predicting, confirming, and displaying functional information derived from genomic sequence
EP1267908B1 (en) * 2000-03-03 2004-05-06 GlaxoSmithKline Biologicals S.A. Vaccine for the treatment of atherosclerosis
SE0000855D0 (sv) * 2000-03-15 2000-03-15 Karolinska Innovations Ab Antigenic composition useful as a vaccine against atherosclerosis
GB0017641D0 (en) * 2000-07-18 2000-09-06 Medigene Oy Peptides and their use
EP1186299A1 (en) * 2000-09-12 2002-03-13 Universitair Medisch Centrum Utrecht The diagnosis, prevention, and/or succesful treatment of atherosclerosis, infectious diseases, and disturbances in the immune system
US20050048062A1 (en) * 2000-10-25 2005-03-03 Vincent Agnello Method of inhibiting infection by hcv, other flaviviridae viruses, and any other virus that complexes to low density lipoprotein or to very low density lipoprotein in blood preventing viral entry into a cell
WO2002042426A2 (en) * 2000-11-10 2002-05-30 University Of Utah Research Foundation Carrier system for specific artery wall gene delivery
SE0103754L (sv) * 2001-04-05 2002-10-06 Forskarpatent I Syd Ab Peptider från apolipoprotein B, användning därav immunisering, diagnosmetod eller terapeutisk behandling av ischemiska kardiovaskulära sjukdomar, samt farmaceutisk komposition och vaccin innehållande sådan peptid
RU2003136090A (ru) * 2001-05-15 2005-04-20 Джэпэн Иммьюнорисерч Лэборэтериз Ко., Лтд (Jp) Пептид, взаимодействующий с липопротеином высокой плотности
WO2003007689A2 (en) * 2001-07-20 2003-01-30 Eidgenoessische Technische Hochschule Zurich (Ethz) Compositions and methods for use of bioactive agents derived from sulfated and sulfonated amino acids

Also Published As

Publication number Publication date
ATE510851T1 (de) 2011-06-15
EP2289917A1 (en) 2011-03-02
PL217858B1 (pl) 2014-08-29
EP2289924A1 (en) 2011-03-02
WO2002080954A1 (en) 2002-10-17
EP2289912A1 (en) 2011-03-02
EP2289926A1 (en) 2011-03-02
AU2002246484B8 (en) 2007-06-14
EP2295460B1 (en) 2015-06-03
JP2011063598A (ja) 2011-03-31
EP2289914A1 (en) 2011-03-02
JP2008169215A (ja) 2008-07-24
EP2289929A1 (en) 2011-03-02
EP2295457A1 (en) 2011-03-16
CN101284874A (zh) 2008-10-15
AU2002246484A1 (en) 2002-10-21
ES2317999T3 (es) 2009-05-01
EP2147930A3 (en) 2010-04-14
SE0103754L (sv) 2002-10-06
AU2002246484B2 (en) 2007-04-19
EP2289919A1 (en) 2011-03-02
CN101486766A (zh) 2009-07-22
EP2147928A3 (en) 2010-04-14
JP5300820B2 (ja) 2013-09-25
EP1383526A1 (en) 2004-01-28
EP2289934B1 (en) 2013-11-13
EP2295464A1 (en) 2011-03-16
EP2006301A1 (en) 2008-12-24
SE0103754D0 (sv) 2001-11-09
CN103122031B (zh) 2015-07-22
CA2443223C (en) 2013-11-26
EP2289922A1 (en) 2011-03-02
EP2295458A1 (en) 2011-03-16
EP2289915A1 (en) 2011-03-02
EP2006301B1 (en) 2011-05-25
EP2305707A1 (en) 2011-04-06
EP2147929A3 (en) 2010-04-14
EP2147680A2 (en) 2010-01-27
EP2289932A1 (en) 2011-03-02
CN1505525A (zh) 2004-06-16
RU2003132443A (ru) 2005-02-27
EP2289930A1 (en) 2011-03-02
JP5300819B2 (ja) 2013-09-25
EP2289923A1 (en) 2011-03-02
IL158285A (en) 2009-12-24
EP2289916A1 (en) 2011-03-02
JP2013144687A (ja) 2013-07-25
EP2295462A1 (en) 2011-03-16
EP2295463A1 (en) 2011-03-16
DK1383526T3 (da) 2009-03-30
CY1108817T1 (el) 2014-04-09
EP2295460A1 (en) 2011-03-16
RU2296582C2 (ru) 2007-04-10
CN101284874B (zh) 2012-10-03
EP2305706A1 (en) 2011-04-06
EP2289935A1 (en) 2011-03-02
PL215401B1 (pl) 2013-12-31
PL367301A1 (en) 2005-02-21
DE60230029D1 (de) 2009-01-08
JP5613890B2 (ja) 2014-10-29
BR0208685A (pt) 2004-03-30
EP2147680A3 (en) 2010-04-14
EP2289921A1 (en) 2011-03-02
EP1383526B1 (en) 2008-11-26
EP2289934A1 (en) 2011-03-02
EP2289933A1 (en) 2011-03-02
CA2827167A1 (en) 2002-10-17
EE200700052A (et) 2008-08-15
EP2289931A1 (en) 2011-03-02
DK2295464T3 (en) 2015-08-17
CN1505525B (zh) 2012-11-07
EP2295461A1 (en) 2011-03-16
CA2443223A1 (en) 2002-10-17
EP2289928A1 (en) 2011-03-02
CA2606839C (en) 2015-06-09
CA2606839A1 (en) 2002-10-17
EP2305708A1 (en) 2011-04-06
IL195356A0 (en) 2009-08-03
EE200300487A (et) 2004-02-16
IL188286A0 (en) 2008-03-20
EP2289913A1 (en) 2011-03-02
ATE415423T1 (de) 2008-12-15
PT1383526E (pt) 2009-02-27
EP2147928A2 (en) 2010-01-27
EP2289925A1 (en) 2011-03-02
EP2295464B1 (en) 2015-06-03
EP2289918A1 (en) 2011-03-02
EP2295459A1 (en) 2011-03-16
JP5270456B2 (ja) 2013-08-21
EP2289927A1 (en) 2011-03-02
JP2009191078A (ja) 2009-08-27
CN103122031A (zh) 2013-05-29
JP2011068654A (ja) 2011-04-07
EP2147929A2 (en) 2010-01-27
PL400308A1 (pl) 2012-12-17
JP2004529143A (ja) 2004-09-24
EP2289920A1 (en) 2011-03-02
EP1918300A3 (en) 2009-06-17
ES2546293T3 (es) 2015-09-22
DK2006301T3 (da) 2011-09-12
EP1918300A2 (en) 2008-05-07
EP2147930A2 (en) 2010-01-27

Similar Documents

Publication Publication Date Title
IL188286A0 (en) Peptide-based immunization therapy for treatment of atherosclerosis and development of peptide-based assay for determination of immune responses against oxidized low density lipoprotein
AT500379B1 (de) Tau-proteine
NO922744D0 (no) Peptidblanding og fremgangsmaate ved paavisning av antistoffer htlv-iii
HK1087018A1 (en) Peptide-based passive immunization therapy for treatment of atherosclerosis
Tian et al. Effect of Rothia mucilaginosa enzymes on gliadin (gluten) structure, deamidation, and immunogenic epitopes relevant to celiac disease
KR970027305A (ko) 인간 혈장 아포지단백질(apolipoprotein) B-100에 결합하는 생쥐 항체를 암호하는 cDNA
DE69635582D1 (de) Diagnostika und behandlungen von peridontalen erkrankungen
DK1167389T3 (da) Antistoffer mod SEMP1-proteinet, fremgangsmåde til fremstilling heraf samt anvendelse deraf
IL160533A0 (en) Methods of screening molecules that are used to prevent cardiovascular diseases
PT723552E (pt) Oligopeptidos derivados de fragmentos de proteina reactiva c
WO2004030607A3 (en) Peptide-based passive immunization therapy for treatment of atherosclerosis
ATE245661T1 (de) Natürliche menschliche igm antikörper
BRPI0216033B8 (pt) "terapia de imunização à base de peptídio para tratamento de arteriosclerose"
DE60336214D1 (de) Methoden zur analyse von antikörperdisulfidisomere
WO2002023202A3 (en) Method to identify antibody targets based on mass spectrometry (maldi-tof)
DK1275638T3 (da) Kombinationspræparat til behandling af immunologiske sygdomme
SE0104354D0 (sv) Peptide-based immunization therapy for treatment of atherosclerosis and development of peptide-based ELISA for determination of immune responses against oxidized low-density lipoprotein